GSK shutdown in Cork to claim 94 jobs; Bayer, Regeneron roll VEGF Trap-Eye development into China, Russia;

@FiercePharma: Novartis nixes $78M non-compete with Chairman Vasella amid frenzy of criticism from Swiss. Report | Follow @FiercePharma

@EricPFierce: Gilead recall raises question about Vistide stocks. Company tells providers to look to generic suppliers. Story | Follow @EricPFierce

@AlisonBFierce: Court: Sanofi is not liable to pay local capital gains tax for its 30B rupee acquisition of Indian vax maker Shantha. More | Follow @AlisonBFierce

> The planned closure of a GlaxoSmithKline ($GSK) financial services operation in Cork, Ireland, is moving ahead, with 94 local jobs to be cut; staffers will be offered the choice of relocating to the operation's new home in the U.K. Report

> Bayer and Regeneron ($REGN) plan to launch new studies of their vision-loss treatment VEGF Trap-Eye in diabetic macular edema patients in China, Russia and other Asian countries; the drug is sold as Eylea in the U.S. Report

> Sanofi's ($SNY) Indian unit wants to double its share of the consumer healthcare business in that country to 4.2% of the 27 billion rupee ($497 million) market. Report

> Actelion ($ATLN) won Japanese approval for the pulmonary arterial hypertension (PAH) treatment epoprostenol "ACT," marketed as Veletri in the U.S. Report

> Low growth in Medicare drug spending has allowed the Part D program to lower copayments and standard deductibles. Report

> FDA issued warning letters to 9 internet distributors of dietary supplements, citing false claims about their products' flu-fighting properties. Report

Biotech News

 @FierceBiotech: Pfizer axes CovX research unit and 100 jobs in San Diego. More | Follow @FierceBiotech

@JohnCFierce: Coronavirus, which killed 5 of the 12 people known to have been infected by it, is suited to spread easily in humans. Report | Follow @JohnCFierce

> Gilead races to FDA after hep C blockbuster hopeful scores 4th win in PhIII. Story

> Roche grabs rights to Chiasma's PhIII rare disease drug in $595M deal. Article

> Analysts assign Phytopharm to scrap heap after decisive Parkinson's failure. News

Pharma News

@FiercePharma: Novartis nixes $78M non-compete with Chairman Vasella amid frenzy of criticism from Swiss. Report | Follow @FiercePharma

@EricPFierce: Gilead recall raises question about Vistide stocks. Company tells providers to look to generic suppliers. Story | Follow @EricPFierce

@AlisonBFierce: Court: Sanofi is not liable to pay local capital gains tax for its 30B rupee acquisition of Indian vax maker Shantha. More | Follow @AlisonBFierce

> GSK, Roche teaming with anti-doping agency. Report

> Novartis nabs another FDA-approved indication for everolimus. More

> Takeda preps for first Actos trial now opening in LA. News

Medical Device News

 @FierceMedDev: PolyActiva pulls in $9.5M for intraocular implant work. Story | Follow @FierceMedDev

 @MarkHFierce: AutoGenomics aborted its second IPO attempt in a few years. The company promises #3, but we'll see. More | Follow @MarkHFierce

 @DamianFierce: In case you missed it over the weekend, Quintiles is finally kicking off the process of going public. News | Follow @DamianFierce

> Medtronic rides emerging markets growth to strong quarter. Story

> NeuroMetrix eyes sales rep expansion for pain device rollout. Article

Biotech Research News

> Antidepressant could reverse sickle cell disease. More

> Nicotinamide slows breast tumor growth in mice. Story

> Human stem cell trial set to begin in Japan. Item

> Compound could restore learning, memory in Angelman syndrome. Article

CRO News

> QPS swings into North Carolina with Hamner partnership. Story

> Charles River predicts strong 2013 despite Q4 slump. More

> With revenue rolling, AMRI looks to CDMO boom in 2013. Article

> Quintiles files IPO worth $600 million--or much more. News

Biotech IT News

> Genomics? There could be an app for that. Item

> Boehringer Ingelheim goes to Hungary for R&D software. More

> EU enters expensive race to map out brain secrets with computers. Article

> CLC bio capitalizes on surge in DNA sequencing. Story

Pharma Manufacturing News

> AMRI 'money pit' now money maker. Item

> GSK commits to continuous processing. More

> Gilead recalls some Vistide; supplies may be an issue. Article

> FDA lambastes Jamaican manufacturer over sterility, quality. Story

And Finally... Scientists created new strains of polio vaccine designed to protect workers in factories where the immunizations are made. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.